Visual and Anatomical Outcomes of Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration

Table 2

Visual and anatomical outcomes after aflibercept conversion.

Outcomes	Baseline	3 months		6 months
			P value^a		P value^a
BCVA (number of ETDRS letters)	42.5 ± 12.5	42.3 ± 10.5	>0.05^b	42.8 ± 10.0	>0.05^b
BCVA (logMAR)	0.24	0.26		0.24
1-mm CSF (microns)	449 ± 179	224 ± 131	<0.001^b	269 ± 145	<0.001^b
Maximum height of PED (microns)	262 ± 134	181 ± 118	<0.001^b	183 ± 100	<0.001^b
Subfoveal choroidal thickness (microns)	192 ± 67	159 ± 58	<0.01^b	167 ± 51	<0.01^b
Presence of intraretinal fluid, number (%)	27 (87)	8 (26)	<0.0001^c	12 (39)	<0.0001^c
Presence of subretinal fluid, number (%)	19 (61)	8 (26)	<0.001^c	8 (26)	<0.001^c
Presence of PED, number (%)	31 (100)	23 (74)	<0.01^c	27 (87)	>0.05^c
Number of aflibercept injections				4.5 ± 1.3

Values are mean ± SD unless otherwise indicated.
BCVA: best-corrected visual acuity; ETDRS: early treatment diabetic retinopathy study; logMAR: logarithm of the minimal angle of resolution; CSF: central subfield retinal thickness; PED: pigment epithelial detachment.
^aCompared with baseline.
^bPaired 𝑡-test.
^cMcNemar’s test.